Summary:
- Moderna has announced positive Phase 3 clinical trial results for its mRNA-4157 (V940) cancer vaccine, developed in collaboration with Merck, specifically targeting high-risk melanoma.
- The study demonstrates a statistically significant improvement in recurrence-free survival, marking a major milestone in the application of mRNA technology—originally developed for COVID-19—to personalized oncology and immunotherapy.